CagriSema explained: what the combo drug is and isn’t

CagriSema refers to a combination of cagrilintide and semaglutide. It is not the same product as Wegovy, Ozempic, or oral semaglutide, even though semaglutide is part of the combination. It is also not an approved medication in the U.S. as of the publish date. If you see it advertised as “available now,” treat that as a red flag and bring it up with your clinician.

Novo Nordisk submitted CagriSema to the FDA on December 18, 2025. As of September 15, 2026, it is still not approved, and an FDA decision is expected by the end of 2026. That means there is no FDA-approved CagriSema prescription you can fill at a U.S. pharmacy today. If your care plan depends on access, focus on options that are currently approved and available.

If you are on a GLP-1 now, it helps to compare any “next” drug to what you can actually access in 2026. Wegovy exists as an injection, and a higher-dose Wegovy HD injection was FDA approved on March 19, 2026 for chronic weight management. There is also a Wegovy pill (oral semaglutide 25 mg), FDA approved in December 2025 and launched in January 2026. Zepbound is available, including the multi-dose Zepbound KwikPen approved in February 2026.

Different pills have very different instructions, and mixing them up can cause problems with adherence. The Wegovy pill must be taken first thing in the morning with a small sip of water, at least 30 minutes before food, drinks, or other oral medicines. Foundayo (orforglipron) is a once-daily GLP-1 pill approved April 1, 2026 and launched April 6, 2026, and it does not require fasting or water restrictions. For any pill, confirm your exact instructions with your prescriber and pharmacist.

Pricing and discount programs change often, so only use numbers that you can confirm at the time you’re making a decision. As of 2026, Foundayo is available via LillyDirect, telehealth, and retail pharmacies, with self-pay starting at $149/month for the lowest dose and a commercial savings card as low as $25/month for eligible patients. TrumpRx.gov can list the lowest manufacturer self-pay prices and route you to NovoCare or LillyDirect, but it is not insurance. If you have Medicare, the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and may cover Wegovy (all forms), Foundayo, and Zepbound KwikPen with prior authorization and a $50/month copay for eligible Part D enrollees.

Ask your prescribing provider what goal you are treating (weight management, cardiometabolic risk, or both) and what options are realistic right now versus “maybe later.” If you are considering switching products or formulations, ask your pharmacist to review administration timing and any concerns with other medicines you take, since interaction questions are individualized. If pregnancy, breastfeeding, fertility, contraception, or hormone therapy is part of your life, discuss it directly with your prescriber or OB-GYN, because GLP-1 medicines are generally not recommended during pregnancy. Also note that tirzepatide can reduce oral contraceptive absorption around starts and dose increases, so this should be planned with your clinician.